Contributions
Abstract: P367
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: Acute idiopathic transverse myelitis (MTAI) is an inflammatory demyelinating disease, with monophasic or recurrent evolution. It may occur as an isolated clinical syndrome or CORE syndrome of the Neuromyelitis Optica (NOM) spectrum disorders. The presence of anti AQP4 in MTAI characterizes it as NOM spectrum disorders, and this reclassification allows the beginning a specific treatment. Another autoantibody has been studied as a biomarker in patients with NOM and high risk AQP4 syndromes, is the anti-MOG (oligodendrocyte myelin glycoprotein).
Objective: To test anti-AQP4 and anti-MOG antibodies in a cohort of patients with MTAI and to describe the clinical, demographic, laboratory and neuroimaging characteristics, analyzing the prognostic values.
Methods: Thirty patients with MTAI (Transverse Myelitis Consortium Working Group, 2002) attended in Rio de Janeiro / Brazil, whose anti-AQP4 and anti-MOG investigations were performed using the Cell Based Assay (CBA) method, from January 2016 to December 2017. Clinical, demographic, laboratory, and neuroimaging data were analyzed. The Expanded Disability Status Scale (EDSS) analyzed the disability in two years from diagnosis.
Results: The majority of the cases were women (83.3%), Afro-descendant (63,3%). Recurrent clinical course was the most prevalent (60%). Neuroimaging studies, observed 60% with extensive lesions (LEMT) and 40% of small lesions (NEMT). In group of LEMT, 44,5% was AQP4 positive patients and one case of LEMT was anti-MOG positive and AQP4 negative. This case is a male, afro-descendant, young age, monophasic course with completely recovery and EDSS zero. A clinical evaluation was analyzed by the median of EDSS; in the group of LEMT, AQP4 positive was 1,5; AQP4 negative, was4,0. In the group of NEMT, de median was 1,0.Conclusion: In Brazilian patients MTAI, the median of EDSS in the group of LEMT AQP4 positive was lower than AQP4 negative group. Finally, the only case with anti-MOG positive was the best EDSS.
Disclosure: Nothing to disclose.
Abstract: P367
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: Acute idiopathic transverse myelitis (MTAI) is an inflammatory demyelinating disease, with monophasic or recurrent evolution. It may occur as an isolated clinical syndrome or CORE syndrome of the Neuromyelitis Optica (NOM) spectrum disorders. The presence of anti AQP4 in MTAI characterizes it as NOM spectrum disorders, and this reclassification allows the beginning a specific treatment. Another autoantibody has been studied as a biomarker in patients with NOM and high risk AQP4 syndromes, is the anti-MOG (oligodendrocyte myelin glycoprotein).
Objective: To test anti-AQP4 and anti-MOG antibodies in a cohort of patients with MTAI and to describe the clinical, demographic, laboratory and neuroimaging characteristics, analyzing the prognostic values.
Methods: Thirty patients with MTAI (Transverse Myelitis Consortium Working Group, 2002) attended in Rio de Janeiro / Brazil, whose anti-AQP4 and anti-MOG investigations were performed using the Cell Based Assay (CBA) method, from January 2016 to December 2017. Clinical, demographic, laboratory, and neuroimaging data were analyzed. The Expanded Disability Status Scale (EDSS) analyzed the disability in two years from diagnosis.
Results: The majority of the cases were women (83.3%), Afro-descendant (63,3%). Recurrent clinical course was the most prevalent (60%). Neuroimaging studies, observed 60% with extensive lesions (LEMT) and 40% of small lesions (NEMT). In group of LEMT, 44,5% was AQP4 positive patients and one case of LEMT was anti-MOG positive and AQP4 negative. This case is a male, afro-descendant, young age, monophasic course with completely recovery and EDSS zero. A clinical evaluation was analyzed by the median of EDSS; in the group of LEMT, AQP4 positive was 1,5; AQP4 negative, was4,0. In the group of NEMT, de median was 1,0.Conclusion: In Brazilian patients MTAI, the median of EDSS in the group of LEMT AQP4 positive was lower than AQP4 negative group. Finally, the only case with anti-MOG positive was the best EDSS.
Disclosure: Nothing to disclose.